GPBAR1 and neoplasm: In AOM/DSS-induced primary CRC mice models, UDCA, acting as a TGR5 agonist, downregulated the YAP pathway, which is linked to tumor growth, reducing the CRC progression, and thus demonstrating a protective effect.